Novavax: CDC approval for 2nd dose of Covid vaccine
(CercleFinance.com) - Novavax announces that the CDC has approved the recommendations of the Advisory Committee on Immunization Practices (ACIP) to administer a second dose of Novavax's COVID-19 2024-2025 vaccine to adults aged 65 and over and to moderately or severely immunocompromised individuals, six months after the first dose.
Additional doses (three or more) are also recommended for immunocompromised individuals in consultation with a healthcare professional.
Novavax's COVID-19 vaccine (formula 2024-2025) is available in over 30,000 locations, including pharmacies, doctors' offices and public health centers across the US.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Additional doses (three or more) are also recommended for immunocompromised individuals in consultation with a healthcare professional.
Novavax's COVID-19 vaccine (formula 2024-2025) is available in over 30,000 locations, including pharmacies, doctors' offices and public health centers across the US.
Copyright (c) 2024 CercleFinance.com. All rights reserved.